These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 30926653)

  • 21. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.
    Akbar SM; Furukawa S; Hasebe A; Horiike N; Michitaka K; Onji M
    Int J Mol Med; 2004 Aug; 14(2):295-9. PubMed ID: 15254781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response.
    Ma Z; Zhang E; Gao S; Xiong Y; Lu M
    Front Immunol; 2019; 10():2308. PubMed ID: 31608073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice.
    Akbar SM; Kajino K; Tanimoto K; Kurose K; Masumoto T; Michitaka K; Horiike N; Onji M
    J Hepatol; 1997 Jan; 26(1):131-7. PubMed ID: 9148003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.
    Chen X; Li M; Le X; Ma W; Zhou B
    Vaccine; 2004 Jan; 22(3-4):439-46. PubMed ID: 14670326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection.
    Akbar SM; Al-Mahtab M; Uddin MH; Khan MS
    Hepatobiliary Pancreat Dis Int; 2013 Aug; 12(4):363-9. PubMed ID: 23924493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes.
    Kato M; Hamada-Tsutsumi S; Okuse C; Sakai A; Matsumoto N; Sato M; Sato T; Arito M; Omoteyama K; Suematsu N; Okamoto K; Kato T; Itoh F; Sumazaki R; Tanaka Y; Yotsuyanagi H; Kato T; Kurokawa MS
    J Gastroenterol; 2017 Sep; 52(9):1051-1063. PubMed ID: 28197802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.
    Huang D; Sansas B; Jiang JH; Gong QM; Jin GD; Calais V; Yu DM; Zhu MY; Wei D; Zhang DH; Inchauspé G; Zhang XX; Zhu R
    J Viral Hepat; 2017 Nov; 24 Suppl 1():66-74. PubMed ID: 29082648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
    Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
    Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B.
    Wen YM; Qu D; Zhou SH
    Int Rev Immunol; 1999; 18(3):251-8. PubMed ID: 10614727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
    Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels.
    Qi R; Fu R; Lei X; He J; Jiang Y; Zhang L; Wu Y; Wang S; Guo X; Chen F; Nie M; Yang M; Chen Y; Zeng J; Xu J; Xiong H; Fang M; Que Y; Yao Y; Wang Y; Cao J; Ye H; Zhang Y; Zheng Z; Cheng T; Zhang J; Lin X; Yuan Q; Zhang T; Xia N
    J Hepatol; 2024 May; 80(5):714-729. PubMed ID: 38336348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection.
    Yum JS; Ahn BC; Jo HJ; Kim DY; Kim KH; Kim HS; Sung YC; Yoon J; Morrey J; Moon HM
    Clin Vaccine Immunol; 2012 Feb; 19(2):120-7. PubMed ID: 22155769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of antiviral - passive - active immunization ("sandwich") therapeutic strategy for functional cure of chronic hepatitis B in mice.
    Shi B; Wu Y; Wang C; Li X; Yu F; Wang B; Yang Z; Li J; Liang M; Wen Y; Ying T; Yuan Z
    EBioMedicine; 2019 Nov; 49():247-257. PubMed ID: 31680000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.
    Boyd A; Canini L; Gozlan J; Lascoux-Combe C; Miailhes P; Fonquernie L; Girard PM; Lacombe K
    J Clin Virol; 2017 Oct; 95():55-60. PubMed ID: 28869890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.
    Schirmbeck R; Melber K; Mertens T; Reimann J
    J Virol; 1994 Mar; 68(3):1418-25. PubMed ID: 8107205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
    Martin P; Dubois C; Jacquier E; Dion S; Mancini-Bourgine M; Godon O; Kratzer R; Lelu-Santolaria K; Evlachev A; Meritet JF; Schlesinger Y; Villeval D; Strub JM; Van Dorsselaer A; Marchand JB; Geist M; Brandely R; Findeli A; Boukhebza H; Menguy T; Silvestre N; Michel ML; Inchauspé G
    Gut; 2015 Dec; 64(12):1961-71. PubMed ID: 25429051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine.
    Wang XY; Zhang XX; Yao X; Jiang JH; Xie YH; Yuan ZH; Wen YM
    Vaccine; 2010 Nov; 28(51):8169-74. PubMed ID: 20937312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.